|Day Low/High||3.30 / 3.42|
|52 Wk Low/High||1.72 / 11.11|
Expected to be final clinical trial prior to 505(b)(2) NDA submission
Company on track for late 2017/early 2018 submission
Data Demonstrate Gimoti Significantly Improves Symptoms in Women with Moderate to Severe Diabetic Gastroparesis
Company reaffirms NDA submission by year end 2017
Nausea and abdominal pain symptoms significantly reduced in patients with higher symptom severity
Healthy volunteer bridging study to oral metoclopramide to be completed and submitted in NDA with existing safety and efficacy data
Evoke Pharma (EVOK) reported a smaller-than-anticipated loss for the 2016 second quarter after Monday's closing bell.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.